Sign in Subscribe
Clinical trials

Diabetic Foot Ulcers Treated with Wharton's Jelly-Derived Mesenchymal Stem Cell Exosomes

Strategic Insights

— 1 min read

Researchers at the National Research Centre in Egypt have found that Wharton's jelly-derived mesenchymal stem cell exosomes can effectively treat diabetic foot ulcers. The treatment showed a significant improvement in wound healing outcomes, with 62% of patients fully recovering within 6 weeks. The study also found that the treated group had a higher percentage of patients who had fully recovered compared to the control group. The researchers believe that MSC-Exos provide a multimodal approach to improve wound healing outcomes in diabetes patients.

Key Takeaways:

  • The study was conducted on 110 individuals with persistent diabetic foot ulcers, who were randomly divided into three groups: treated with Wharton's jelly-derived mesenchymal stem cell exosomes, control, and placebo.
  • The treated group showed a significant improvement in wound healing outcomes, with 53 patients (62%) fully recovering by the end of the study.
  • The treated group's mean time to fully recover was 6 weeks, compared to 20 weeks for the controls.
  • The study found that MSC-Exos provide a multimodal approach to improve wound healing outcomes in diabetes patients.
  • The researchers believe that this treatment option can improve clinical outcomes for diabetic foot ulcers and reduce the risk of amputation.
  • The study was funded by the National Research Centre Egypt, and the research was published in Stem Cell Research & Therapy.

Statistics:

  • 110 individuals with persistent diabetic foot ulcers participated in the study.
  • 53 patients (62%) in the treated group fully recovered by the end of the study.
  • The treated group's mean time to fully recover was 6 weeks (range: 4-8 weeks).
  • The controls were 20 weeks (range: 12-28 weeks).
  • 62% of patients in the treated group had fully recovered, compared to the control group.
  • The study proved that MSC-Exos is a viable treatment option for diabetic foot ulcers.

Sources:

  • The transforming role of wharton's jelly mesenchymal stem cell-derived exosomes for diabetic foot ulcer healing: a randomized controlled clinical trial. Stem Cell Research & Therapy, 2025;16(1):559.
  • Bmc, Campus, 4 Crinan St, London N1 9XW, England.
  • NewsRx. Research from National Research Centre Reveals New Findings on Foot Ulcers (The transforming role of wharton's jelly mesenchymal stem cell-derived exosomes for diabetic foot ulcer healing: a randomized controlled clinical trial). Clinical Trials Week. October 27, 2025; p 479.

Read more